On Wednesday, JD.com, Inc. (NASDAQ:JD)’s shares gained 5.35%, and closed at $32.66, after China’s largest online direct sales corporation, declared UNIQLO as the newest international brand to partner with the corporation by opening a flagship store on its marketplace platform.
The new UNIQLO flagship store is part of JD.com’s industry-leading marketplace, which is increasingly becoming the platform of choice for both domestic and internationally renowned brands and manufacturers seeking to reach the corporation’s massive base of active Chinese shoppers. The addition of UNIQLO adds to JD.com’s growing reputation as the go-to destination for shoppers looking for authentic, high-quality goods in a broad and growing range of categories.
To commemorate the partnership, the new UNIQLO online store will offer special UT (UNIQLO T-shirt) designs, called “Born in China,” which were jointly developed by JD.com and UNIQLO. JD.com customers will also have exclusive access to specially discounted items offered by UNIQLO between April 9 and 16. Upon the April 17 official launch, customers will be able to buy a wide range of UNIQLO products on JD.com’s main website, in addition to through the corporation’s apps and a Weidian store on Tencent’s popular Weixin messaging app (the Chinese version of WeChat).
UNIQLO will also become the first international clothing brand on JD.com’s marketplace platform to warehouse its merchandise in the corporation’s facilities. By using JD.com’s complete logistics solution, UNIQLO is enabling customers in eligible areas to take advantage of JD.com’s unparalleled same- and next-day delivery service.
Beijing Jingdong Century Trading Co., Ltd. operates as an online retailer in China. It retails various categories of products to customers worldwide. The corporation was founded in 1998 and is based in Shanghai, China.
Kite Pharma, Inc. (NASDAQ:KITE)’s shares jumped 5.18%, and settled at $58.47, during the last trading session on Wednesday, after Kite Pharma declared articles being published in the current issue of Science, one article by the Corporation’s Cooperative Research and Development Contract (CRADA) collaborators at the National Cancer Institute (NCI) and the second article by the Netherlands Cancer Institute (NKI). The first article, “Adoptive Cell Transfer as personalized immunotherapy for human cancer,” was authored by Steven A. Rosenberg, M.D., Ph.D., Chief of Surgery at the NCI, and his colleague Nicholas P. Restifo, M.D., Senior Investigator at NCI’s Surgery Branch. The second article, “Neoantigens in cancer immunotherapy,” was written by Professor Dr. Ton N. M. Schumacher, Ph.D., Deputy Director of NKI, and Robert D. Schreiber, Ph.D., Director, Center for Human Immunology and Immunotherapy Programs, at Washington University School of Medicine. Professor Schumacher also serves as Chief Scientific Officer of Kite Pharma EU.
In their article, Drs. Rosenberg and Restifo reviewed the development of adoptive cell therapy, counting the advent of genetically modified T cells and their promising results in patients with multiple tumor types. Last month, Kite declared an expansion of its CRADA with the Surgery Branch at the NCI, led by Dr. Rosenberg. The amendment encompasses emerging areas of research in the immune response to tumor neoantigens, in addition to new T cell receptor (TCR) and chimeric antigen receptor (CAR) product candidates targeting solid tumors.
Kite Pharma, Inc., a clinical-stage biopharmaceutical corporation, focuses on the development and commercialization of novel cancer immunotherapy products. The corporation is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies.
At the end of Wednesday’s trade, Rambus Inc. (NASDAQ:RMBS)’s shares climbed 5%, and closed at $13.55, after a technology solutions corporation, declared that its Cryptography Research Division has reached a partnership contract with Barco Silex. Through this contract, Barco Silex can develop DPA-resistant solutions that assist accelerate time-to-market of security-based products. Barco Silex will utilize Cryptography Research differential power analysis, or DPA, countermeasure technology to assist protect against security risks in a variety of point-of-sale applications, counting banking, retailing, mass transit, and wireless telecommunications.
Concerns about DPA security attacks originated in the smartcard market; however, the potential for these attacks is spreading into many other markets. For this reason, there is a need for DPA countermeasures to be adopted across all markets where valuable financial and personal data is being handled. Recently, products ordinarily at risk comprise point-of-sale devices, mobile phones, secure USB flash drives, pay television set-top boxes, and optical disc players among others.
Barco Silex has joined the Rambus Partner Program, which will enable further partnershipon other combined IP blocks offerings between the two companies.
Rambus Inc. operates as a technology solutions corporation in South Korea, the United States, Japan, Europe, Canada, Asia, and internationally. The corporations technology solutions comprise memory, chip interfaces and architectures, end-to-end security, and advanced LED lighting. It focuses on designing, developing, and licensing technology that is related to memory and interfaces; and providing various services, counting know-how and technology transfer, product design and development, system integration, and other services.
Amarin Corporation plc (NASDAQ:AMRN), ended its Wednesday’s trading session with 4.96% gain, and closed at $2.54, after a biopharmaceutical corporation, and Walk with a Doc, a national nonprofit organization, declared a 2015 partnership to expand the reach of their national health awareness efforts.
Walk with a Doc is a free participation, year-round walking program held in communities across the United States and abroad. The program is dedicated to encouraging healthy physical activity in people of all ages with the aim of reversing the consequences of a sedentary lifestyle and improving health and well-being. Each walk is hosted by local physicians in public spaces and everyone is welcome.
The education that Walk with a Doc does in local communities on the issues of lack of diet and exercise fits well with Amarin’s Lower My Trigs™ campaign. Lower My Trigs™ is a national awareness initiative that features Rick Harrison, Star of the hit television show “Pawn Stars”® and encourages those with very high triglycerides to exercise, diet and learn more about the health issues associated with this condition.
Amarin Corporation plc, a biopharmaceutical corporation, focuses on developing and commercializing therapeutics for the treatment of cardiovascular diseases in the United States. The corporation’s lead product comprises Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content comprised of in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve talk aboutions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as anticipates, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
